Data on administration of cyclosporine, nicorandil, metoprolol on reperfusion related outcomes in ST-segment Elevation Myocardial Infarction treated with percutaneous coronary intervention.
197 - 205
Data in Brief
MetadataShow full item record
Mortality and morbidity in patients with ST elevation myocardial infarction (STEMI) treated with primary percutaneous coronary intervention (PCI) are still high . A huge amount of the myocardial damage is related to the mitochondrial events happening during reperfusion . Several drugs directly and indirectly targeting mitochondria have been administered at the time of the PCI and their effect on fatal (all-cause mortality, cardiovascular (CV) death) and non fatal (hospital readmission for heart failure (HF)) outcomes have been tested showing conflicting results , , , , , , , , , , , , , . Data from 15 trials have been pooled with the aim to analyze the effect of drug administration versus placebo on outcome . Subgroup analysis are here analyzed: considering only randomized clinical trial (RCT) on cyclosporine or nicorandil , , , , , , excluding a trial on metoprolol  and comparing trial with follow-up length <12 months versus those with longer follow-up , , , , , , , , , , , , , . This article describes data related article titled "Clinical Benefit of Drugs Targeting Mitochondrial Function as an Adjunct to Reperfusion in ST-segment Elevation Myocardial Infarction: a Meta-Analysis of Randomized Clinical Trials" .
AuthorsCampo, G; Pavasini, R; Morciano, G; Lincoff, MA; C Gibson, M; Kitakaze, M; Lonborg, J; Ahluwalia, A; Ishii, H; Frenneaux, M; Ovize, M; Galvani, M; Atar, D; Ibanez, B; Cerisano, G; Biscaglia, S; Neil, BJ; Asakura, M; Engstrom, T; Jones, DA; Dawson, D; Ferrari, R; Pinton, P; Ottani, F
- Cardiovascular